SCHEMBL923979

SCHEMBL923979

CCn1cc(Cl)nc(Cl)c1=O

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.36
ALDH1A1 P00352 5/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
BAZ2A Q9UIF9 1/20 0.33
HPGD P15428 2/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 2/20 0.33
NPC1 O15118 1/20 0.33
HSP90AA1 P07900 1/20 0.33
MAPT P10636 1/20 0.33
XBP1 P17861 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TLR9 Q9NR96 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923653 0.81 BRD4 (0.35) BRD4ALDH1A1SMN1; SMN2BAZ2AHPGD
SCHEMBL4871665 0.77 BRD4 (0.35) BRD4ALDH1A1SMN1; SMN2BAZ2A
SCHEMBL28746277 0.75 BRD4 (0.35) BRD4ALDH1A1SMN1; SMN2BAZ2A
SCHEMBL16644650 0.74 CNOT7 (0.38) BRD4ALDH1A1BAZ2AHPGDLMNA
SCHEMBL644097 0.74 ALDH1A1 (0.59) BRD4ALDH1A1SMN1; SMN2HPGDLMNA
SCHEMBL28223263 0.72
SCHEMBL859740 0.72 BRD4 (0.39) BRD4ALDH1A1SMN1; SMN2BAZ2AHPGD
SCHEMBL644390 0.72 MAPT (0.49) LMNAMAPTNPSR1
SCHEMBL12907306 0.71 ALDH1A1 (0.33) ALDH1A1HPGDLMNA
SCHEMBL25793112 0.71 POLB (0.32) ALDH1A1SMN1; SMN2MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
US-9102632-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2015-08-11 US disclosed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP disclosed
EP-2250156-B1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2015-05-06 EP disclosed
CN-101945858-B Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH 2014-05-21 CN disclosed
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2014-04-10 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-8637522-B2 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes MERCK PAATENT GESELLSCHAFT (DE) 2011-01-20 US disclosed
EP-2250156-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES Merck Patent GmbH (DE) 2010-11-17 EP disclosed
WO-2009109259-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-11 WO disclosed
WO-2009109259-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES MERCK PATENT GMBH (DE) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140100235-A1 PYRAZINONE DERIVATIVES AS INSULIN SECRETON STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES GLP1R, GPR119, IAPP BRD4 2509/4885ALDH1A1 3746/4885SMN1; SMN2 4088/4885
US-20110015210-A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes GLP1R, IAPP, INSR BRD4 2323/4885ALDH1A1 2942/4885SMN1; SMN2 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.